Table 3. Distribution of minimum inhibitory concentrations and resistance determinants of *S*. Enteritidis in Thailand.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Drugs** | **Resistance determinants** | | **Total No.** | **Number of isolates according to MIC (mg/L)** | | | | | | | | | | | | | | | | | | | | |
| ***gyrA*** genotypes | ***qnrS*** | **0.032** | **0.047** | **0.064** | **0.094** | **0.125** | **0.19** | **0.25** | **0.38** | **0.5** | **0.75** | **1** | **1.5** | **2** | **3** | **4** | **8** | **16** | **24** | **32** | **64** | **≥256** |
| **NAL** | wild type (n=20) | +  - | 18 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 | 10 | 3 |  |  |
|  |  | -  - | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
|  | Mutants (n=138) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Ile | - | 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 |
|  | Ser83Phe | - | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
|  | Ser83Tyr | - | 39 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 38 |
|  | + | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
|  | Asp87Asn | - | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
|  | Asp87Gly | - | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
|  | Asp87Tyr | - | 83 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  | 82 |
|  | Ser83Phe/Asp87Tyr | - | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
| **NOR** | wild type (n=20) | +  - | 18 |  |  |  |  |  |  |  |  |  |  | 2 | 12 | 4 |  |  |  |  |  |  |  |  |
|  |  | -  - | 2 |  |  |  |  |  |  |  |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |
|  | Mutants (n=138) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Ile | - | 8 |  |  |  |  |  |  | 1 | 1 | 1 | 1 | 4 |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Phe | - | 2 |  |  |  |  |  |  |  |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Tyr | - | 39 |  |  |  |  |  |  | 5 |  | 5 | 9 | 13 | 6 | 1 |  |  |  |  |  |  |  |  |
|  |  | + | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |
|  | Asp87Asn | - | 2 |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |
|  | Asp87Gly | - | 2 |  |  |  |  |  |  | 1 |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Asp87Tyr | - | 83 |  |  |  |  |  | 1 | 2 | 1 | 28 | 34 | 11 | 2 | 3 | 1 |  |  |  |  |  |  |  |
|  | Ser83Phe/Asp87Tyr | - | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |
| **CIP** | wild type (n=20) | +  - | 18 |  |  |  |  |  |  | 1 | 16 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | -  - | 2 |  |  |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Mutants(n=138) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Ile | - | 8 |  |  |  | 2 |  | 1 | 2 | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Phe | - | 2 |  |  |  |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Tyr | - | 39 |  | 4 | 1 | 2 | 4 | 13 | 13 | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | + | 1 |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |
|  | Asp87Asn | - | 2 |  |  |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Asp87Gly | - | 2 | 1 |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Asp87Tyr | - | 83 | 1 | 2 | 1 | 12 | 49 | 10 | 5 |  | 2 |  | 1 |  |  |  |  |  |  |  |  |  |  |
|  | Ser83Phe/Asp87Tyr | - | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

MIC, minimum inhibitory concentration. CIP, ciprofloxacin; NAL, nalidixic acid; NOR, norfloxacin.